Marvel Biosciences Corp. (MRVL.V)
TSXV · CAD · Healthcare · Biotechnology
CA$0.12 (-4.00%) as of
Key statistics
- Market cap
- 8.84M
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.0950 – 0.2500
- Beta
- 0.49
- Profit margin
- 0.00%
- Volume
- 85.61k
About Marvel Biosciences Corp.
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Calgary, AB, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.